| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Charles River Laboratories International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$217.60 |
| 52 Week High | US$251.80 |
| 52 Week Low | US$154.45 |
| Beta | 1.41 |
| 1 Month Change | -13.58% |
| 3 Month Change | 11.48% |
| 1 Year Change | 28.91% |
| 3 Year Change | -20.58% |
| 5 Year Change | 72.97% |
| Change since IPO | 707.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| RV6 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.3% | -4.6% | 1.8% |
| 1Y | 28.9% | -8.0% | 2.2% |
Return vs Industry: RV6 exceeded the German Life Sciences industry which returned -8% over the past year.
Return vs Market: RV6 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| RV6 volatility | |
|---|---|
| RV6 Average Weekly Movement | 4.8% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RV6 has not had significant price volatility in the past 3 months.
Volatility Over Time: RV6's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 21,100 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Charles River Laboratories International, Inc. Fundamentals Summary
| RV6 fundamental statistics | |
|---|---|
| Market cap | €11.54b |
| Earnings (TTM) | €444.06m |
| Revenue (TTM) | €3.86b |
26.0x
P/E Ratio3.0x
P/S RatioIs RV6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RV6 income statement (TTM) | |
|---|---|
| Revenue | US$4.13b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$1.53b |
| Other Expenses | US$1.05b |
| Earnings | US$474.62m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 9.24 |
| Gross Margin | 37.03% |
| Net Profit Margin | 11.49% |
| Debt/Equity Ratio | 71.7% |
How did RV6 perform over the long term?
See historical performance and comparison